一种用于评估肺炎链球菌和金黄色葡萄球菌中氟喹诺酮类药物外排可能参与情况的便捷检测方法：莫西沙星、司帕沙星和曲伐沙星外排减少的证据
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
作者信息
Beyer R, Pestova E, Millichap J J, Stosor V, Noskin G A, Peterson L R
机构信息
Department of Pathology, Division of Microbiology, Northwestern University Medical School, Chicago, Illinois 60611, USA.
出版信息
Antimicrob Agents Chemother. 2000 Mar;44(3):798-801. doi: 10.1128/AAC.44.3.798-801.2000.
Abstract
We developed a simplified assay for estimating efflux by measuring the effect of reserpine on the growth of Streptococcus pneumoniae and Staphylococcus aureus over 7 h. Reserpine enhanced ciprofloxacin and levofloxacin 17 to 68%. The hydrophobic drug trovafloxacin and the drug moxifloxacin, with a bulky C-7 substituent but hydrophilicity similar to that of levofloxacin, showed little (0 to 11%) reserpine-enhancing effect. The ease of resistant mutant strain selection correlated with efflux susceptibility.
摘要
我们开发了一种简化的测定方法，通过测量利血平对肺炎链球菌和金黄色葡萄球菌7小时生长的影响来估算外排情况。利血平使环丙沙星和左氧氟沙星的作用增强了17%至68%。疏水性药物曲伐沙星以及具有庞大C-7取代基但亲水性与左氧氟沙星相似的莫西沙星，显示出很小的（0%至11%）利血平增强作用。耐药突变株选择的难易程度与外排敏感性相关。
相似文献
1
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
Antimicrob Agents Chemother. 2000 Mar;44(3):798-801. doi: 10.1128/AAC.44.3.798-801.2000.
2
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
J Antimicrob Chemother. 1998 Dec;42(6):807-10. doi: 10.1093/jac/42.6.807.
3
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
J Antimicrob Chemother. 2001 Sep;48(3):365-74. doi: 10.1093/jac/48.3.365.
4
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Clin Microbiol Infect. 2000 Dec;6(12):678-81. doi: 10.1046/j.1469-0691.2000.00166.x.
5
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Antimicrob Agents Chemother. 1999 Feb;43(2):421-3. doi: 10.1128/AAC.43.2.421.
6
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Clin Microbiol Infect. 2002 Jun;8(6):373-80. doi: 10.1046/j.1469-0691.2002.00405.x.
7
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
8
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Antimicrob Agents Chemother. 2001 Mar;45(3):673-8. doi: 10.1128/AAC.45.3.673-678.2001.
9
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
10
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
J Antimicrob Chemother. 2000 May;45(5):583-90. doi: 10.1093/jac/45.5.583.
引用本文的文献
1
Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules.
Monatsh Chem. 2018;149(7):1199-1245. doi: 10.1007/s00706-018-2215-x. Epub 2018 Jun 7.
2
Trends in antibiotic resistance in bacterial keratitis isolates from South India.
Br J Ophthalmol. 2017 Feb;101(2):108-113. doi: 10.1136/bjophthalmol-2016-308487. Epub 2016 Apr 29.
3
Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.
Korean J Physiol Pharmacol. 2015 Mar;19(2):99-104. doi: 10.4196/kjpp.2015.19.2.99. Epub 2015 Feb 25.
4
Prevalence and antimicrobial resistance of Enterococcus species: a hospital-based study in China.
Int J Environ Res Public Health. 2014 Mar 21;11(3):3424-42. doi: 10.3390/ijerph110303424.
5
Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.
Pharm Res. 2014 May;31(5):1290-301. doi: 10.1007/s11095-013-1250-x. Epub 2013 Dec 5.
6
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
Bioorg Med Chem Lett. 2012 Oct 15;22(20):6513-20. doi: 10.1016/j.bmcl.2012.05.026. Epub 2012 Jul 1.
7
Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA.
Ann Clin Microbiol Antimicrob. 2009 Jun 17;8:21. doi: 10.1186/1476-0711-8-21.
8
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
Antimicrob Agents Chemother. 2008 May;52(5):1677-85. doi: 10.1128/AAC.01644-07. Epub 2008 Mar 24.
9
Fluoroquinolone-resistant mutants of Burkholderia cepacia.
Antimicrob Agents Chemother. 2008 Mar;52(3):1201-3. doi: 10.1128/AAC.00799-07. Epub 2007 Dec 26.
10
A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM.
J Bacteriol. 2007 Oct;189(19):6870-81. doi: 10.1128/JB.00805-07. Epub 2007 Jul 20.
本文引用的文献
1
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
2
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
N Engl J Med. 1999 Jul 22;341(4):233-9. doi: 10.1056/NEJM199907223410403.
3
Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine.
Antimicrob Agents Chemother. 1999 Apr;43(4):988-9. doi: 10.1128/AAC.43.4.988.
4
Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
J Antimicrob Chemother. 1998 Dec;42(6):683-8. doi: 10.1093/jac/42.6.683.
5
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1999 Jan;43(1):187-9. doi: 10.1128/AAC.43.1.187.
6
Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
Clin Infect Dis. 1998 Aug;27 Suppl 1:S54-63. doi: 10.1086/514923.
7
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Aug;42(8):2032-5. doi: 10.1128/AAC.42.8.2032.
8
The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin.
J Antimicrob Chemother. 1997 Sep;40(3):458-60. doi: 10.1093/jac/40.3.458.
9
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1997 Sep;41(9):1973-8. doi: 10.1128/AAC.41.9.1973.
10
Natural functions of bacterial multidrug transporters.
Trends Microbiol. 1997 Aug;5(8):309-13. doi: 10.1016/S0966-842X(97)01064-0.
Zotero 插件